Clinical study: Early prediction of tumor response using imaging and molecular biomarkers of hormone sensitive breast cancer in neoadjuvant hormonal therapy setting

Clinical study: Early prediction of tumor response using imaging and molecular biomarkers of hormone sensitive breast cancer in neoadjuvant hormonal therapy setting - Imaging and molecular biomarker study of hormone sensitive breast cancer in neoadjuvant hormonal therapy setting

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013815

Enrollment

Registered

2014-04-25

Start date

2014-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormonal sensitive breast cancer

Interventions

Letrozole 2.5mg/day daily p.o.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Clinical tumor size 3cm or more 2. cN0 or cN1 3. M0 or M1 4. ERand/or PgR positive and HER2 negative 5. Normal range of routine lab data 6. Patients whom doctors in charge consider benefit of hormane therapy 7. Patients who have accept study participation under document

Exclusion criteria

Exclusion criteria: Patients who have already underwent chemotherapy or hormonal therapy

Design outcomes

Primary

Measure	Time frame
Clinical response rate	—

Secondary

Measure	Time frame
SUV change rate by PET,Labeling index by Ki-67,Hb change rate by DOSI,DFS,OS	—

Countries

Japan

Contacts

Public ContactMIchiko Sugiyama

Saitama International Medical Center Department of breast oncology

syueda@saitama-med.ac.jp81-42-984-4670

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026